GT Biopharma posts Q3 net loss; R&D expenses rise
Overview
Immuno-oncology firm posts Q3 net loss of $3.5 mln vs prior-year net income
R&D expenses rose yr/yr due to higher material costs; SG&A expenses declined
Company ended Q3 with $10 mln cash, expects runway into Q3 2027
Outlook
Company expects to provide updates on both its Phase 1 programs in Q4 2026
Initiation of Phase 1 trial for GTB-5550 in multiple myeloma depends on grant funding timing
Company anticipates cash runway sufficient to fund operations into Q3 2027
Result Drivers
R&D SPENDING - Co said higher Q3 R&D expenses were primarily due to increased material costs for clinical development of GTB-3650 and GTB-5550
LOWER SG&A COSTS - Co said Q3 SG&A expenses fell due to reduced consulting and marketing costs
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Net Loss | $3.50 mln | ||
Q3 Income From Operations | -$3.50 mln |
Reuters Recommended Reads
Nov 13 - PDS Biotechnology Q3 net loss narrows on lower R&D costs
Nov 13 - Aardvark Therapeutics Q3 net loss widens, misses estimates
Nov 13 - Inhibrx Q3 net loss widens on higher G&A expenses
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)